EORTC protocol 75111 - 10114

Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH/PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group
Trial StatusRecruiting
DatesDate of activation:
Data management at EORTCFull
Phase2
Randomized trialYes
TypeAdvanced
Targeted Sample sizeEORTC Groups: 80 - All Groups: 80
Number of steps1
DrugCyclophosphamide
Pertuzumab
Trastuzumab
Trastuzumab emtansine
Study StaffHans P.M.W. Wildiers (Study Coordinator) - U.Z. Leuven - Campus Gasthuisberg, Leuven
Jan Bogaerts (Statistician) - EORTC Headquarters, Brussels
Roel Goossens (Data Manager) - EORTC Headquarters, Brussels
Athanasios Pallis (Coordinating Physician) - EORTC Headquarters, Brussels
Nicolas Dif (Project Manager) - EORTC Headquarters, Brussels, nicolas.dif( at )eortc.be, +32 27741043
Type of cancerBreast
Participating GroupsEORTC Cancer in Elderly Task Force(Coordinating Group)
EORTC Breast Cancer Group
Centers authorized by EORTC
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT01597414
EudraCT2011-006342-32
Protocol documents in PDF
(requires password)		Study documentation
Back to Protocol section